IntelGenx, Circ Pharma to develop hyperlipidemia drug
IntelGenx has formed a partnership with Circ Pharma to formulate, manufacture and supply Circ with a new drug product for the treatment of hyperlipidemia, which Circ will develop and commercialize.
Under the terms of the agreement, the Dublin, Ireland-based Circ will fund the development of the product and IntelGenx will receive royalties from the product's sales. The Saint Laurent, Quebec-based IntelGenx said it will use its proprietary Versatab technology to formulate the product.
The companies said that this is the first product in a series of Circ’s controlled release lipid-lowering agents designed to target the absorption of drug to reduce the dose and potentially lower the side effects. They expect that the product will reach the market in 2012.
Under the terms of the agreement, the Dublin, Ireland-based Circ will fund the development of the product and IntelGenx will receive royalties from the product's sales. The Saint Laurent, Quebec-based IntelGenx said it will use its proprietary Versatab technology to formulate the product.
The companies said that this is the first product in a series of Circ’s controlled release lipid-lowering agents designed to target the absorption of drug to reduce the dose and potentially lower the side effects. They expect that the product will reach the market in 2012.